Glaukos Corporation (GKOS) Quote

GKOS new 52 week high

GKOS new 52 week high

GKOS new 52 week high

This could run hard with volume

I put a bid in on the Aug. 20th 60s

Priced a little high for me. I was hoping to sell into a push to $60-61 .... the $60 options are $1.80 (expire this week).

Would be interesting to know how much shorts covered yesterday.

Given the fight back in WSB tickers, trades based on short covering may not be good ... especially in low volume summer.

Seems low floaters are all the rage right now.

I was thinking about buying some $60 call options

Anyone else trading this hoping it can test $60?

Typically institutional shorts will give it some support on these bigger stocks when they move like this.

Heard we got news today

Glaukos Announces FDA Approval for the iStent inject® Trabecular Micro-Bypass System.

Source:

https://www.yahoo.com/amphtml/finance/news/glaukos-announces-fda-approval-istent-110000994.html?soc_src=social-sh&soc_trk=tw&__twitter_impression=true

$GKOS

GKOS buy 30.3

bull flag



















normal chart




log chart

I am up over 23k here!

GKOS WEEKLY

GKOS 10 MINUTES

GKOS DAY

The FA looks great, but the stock is falling in price.
INTERESTING.

Today : Tuesday 10 November 2015

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced financial results for the third quarter ended September 30, 2015. Key highlights of the quarter, compared to the same period in 2014, include:
• Achieved 57% growth in net sales to $19.0 million, compared to $12.1 million
• Expanded gross margin to approximately 83%, compared to 81%
• Delivered 8% reduction in loss from operations to $1.7 million, compared to $1.9 million
• Paid off $7.0 million in debt and terminated bank loan facility without prepayment penalty
• Following completion of an initial public offering on June 30, 2015, finished the third quarter with net cash and cash equivalents of $93.3 million, compared to $2.3 million at year-end 2014

“Glaukos has delivered another quarter of record performance that demonstrates the momentum building behind our first-in-class iStent technology as an elegant solution for managing intraocular pressure associated with glaucoma,” said Thomas Burns, president and CEO of Glaukos. “The iStent is the first in a series of proprietary, market-expanding glaucoma therapies we are preparing to introduce in the coming years. Our goal is to transform glaucoma treatment with a family of precision, micro-scale injectable therapies that can be used individually or in combination to address the full range of glaucoma disease states and progression.”

Third Quarter 2015 Financial Results

Glaukos net sales rose 57% in the third quarter of 2015 to $19.0 million, compared to $12.1 million in the same period in 2014. The growth was driven by increased adoption of the company’s flagship iStent® Trabecular Micro-Bypass Stent.

Gross margin for the third quarter of 2015 increased to approximately 83%, compared to approximately 81% in the same period in 2014. The gross margin expansion was due primarily to the company’s ability to leverage its fixed manufacturing overhead costs against higher sales.

Operating expenses for the third quarter of 2015 were $17.4 million, up 48% compared to $11.8 million in the same period in 2014. The increase primarily reflected higher personnel, travel and other costs associated with the ongoing expansion of the company’s global infrastructure and sales organization.

Loss from operations in the third quarter of 2015 was $1.7 million, compared to $1.9 million in the third quarter of 2014.

The company reported a net loss attributable to Glaukos shareholders of $2.1 million, or $0.07 per diluted share, in the third quarter of 2015, compared to $1.5 million, or $0.64 per diluted share, in the same period one year ago. The year-over-year reduction in diluted net loss per share primarily reflects the increase in weighted average shares in the third quarter of 2015 resulting from the company’s initial public offering on June 30, 2015 in which Glaukos sold 6.9 million newly issued common shares.

As of September 30, 2015, cash and cash equivalents were $93.3 million, compared to $2.3 million at the end of 2014. The increase primarily reflects the addition of $113.6 million in net cash proceeds from the company’s initial public offering, offset by cash used to fund its operations and $15.0 million used to purchase certain assets from DOSE Medical Corporation. In addition, during the third quarter, the company used approximately $7.0 million in cash to pay off and terminate its bank loan facility.

2015 Revenue Guidance

The company expects 2015 full-year net sales to be in the range of $70.5 million to $71.5 million.

Webcast & Conference Call

The company will host a conference call and simultaneous webcast today at 1:30 p.m. PST (4:30 p.m. EST) to discuss the third quarter results. A link to the webcast is available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 877-201-0168 (U.S.) or 647-788-4901 (international) and enter Conference ID 65750274. A replay of the webcast will be archived on the company’s website immediately following completion of the call and will be available until February 10, 2016.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent®, its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. The company believes the iStent, measuring 1.0 mm long and 0.33 mm wide, is the smallest medical device ever approved by the FDA.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this presentation. These potential risks and uncertainties include, without limitation, the extent to which we will be able to introduce market-expanding glaucoma therapies in the coming years and expectations regarding our financial results. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law. The known risks, uncertainties and factors are described in detail under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission. These are available in the Investor section of our website at www.glaukos.com or at www.sec.gov.

GKOS D

GKOD D 4 MONTHS

float 13.85 m

WEB SITE


http://investors.glaukos.com

Second Quarter 2015 Financial Results

Glaukos net sales rose 60% in the second quarter of 2015 to $17.8 million, compared to $11.1 million in the same period in 2014. The growth was driven by increased adoption of the company’s flagship iStent® Trabecular Micro-Bypass Stent.

GKOS 30 D W M PF

NEW IPO